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Pharmacy Practice Research – A Call to Action 1 
 2 
Introduction to Pharmacy Practice Research  3 
Pharmacists have a societal duty of care. How to best provide that type of care requires a scientific 4 
approach. Pharmacy practice research is a type of health services research. Although there is no 5 
universally accepted definition for pharmacy practice research, the International Pharmaceutical 6 
Federation Pharmacy Practice Special Interest Group (FIP PPR SIG), has defined it as the scientific 7 
discipline that studies the different aspects of the practice of pharmacy, and its impact on health care 8 
systems, medicine use, and patient care. The scope of pharmacy practice’s research has expanded 9 
over the past 50 years to encompass clinical, behavioural, economic, and humanistic implications of 10 
the practice of pharmacy, as well as practice change and implementation of innovations such as 11 
health interventions and patient-care services in routine practice. These are often provided in 12 
collaboration with other health care professionals, supporting an interdisciplinary care and 13 
integrated healthcare delivery. The drive for the expanded role of pharmacists in most settings has 14 
undoubtedly been stimulated by patient demand, a natural professional evolution, but also 15 
facilitated by pharmacy practice research. As such, pharmacy practice research will continue to assist 16 
in shaping the future of the pharmacy profession. 17 
It has been said that “professions exist to serve society”1, otherwise, especially with the technological 18 
revolution, they will disappear. The mission of the pharmacy profession must address the medicines 19 
and health needs of individual patients and the society1  which have changed over the past decades. 20 
The traditional roles of pharmacists have been historically focused on drug compounding and then 21 
on drug supply. These were originally challenged by the clinical pharmacy movement and then by the 22 
concept of Pharmaceutical Care, defined as “the responsible provision of drug therapy for the 23 
purpose of achieving definite outcomes that improve a patient’s quality of life” 2. These changes have 24 
led to emerging roles for the pharmacy profession, mainly through the provision of health 25 
interventions and patient-care services, aiming at either optimizing the medication use process or at 26 
improving health 3,4.  27 
Evidence-based practice requires that healthcare decisions are made based on the best available, 28 
current, valid, and relevant evidence5. Evidence-based practice is essential to deliver high quality 29 
patient care. Over the past years, pharmacy has increasingly used research to evaluate a wide range 30 
of new pharmacist-led services and interventions and their contribution to existing and new models 31 




provided supporting evidence for the role of pharmacists in improving clinical, economic and 33 
humanistic outcomes in different conditions and populations 6–15. Designing feasible patient-care 34 
services and generating robust evidence of their impact (not only for patients but also for the 35 
different stakeholders involved in healthcare) is essential to influence policies that support their 36 
implementation and funding. Based on this evidence, researchers and pharmacy leaders called for 37 
patients, governments, and health insurance companies to remunerate pharmacists for their patient-38 
care services. As a result, services such as medication reviews, smoking cessation counselling, minor 39 
ailment programs, chronic disease management, or vaccinations have been remunerated in various 40 
countries 16,17.  41 
A large number of these innovations are not yet fully integrated into routine practice of pharmacists 42 
and the healthcare system, mainly due to lack of implementation programs and evidence-based 43 
implementation strategies18. These services will only continue to be remunerated if their ongoing 44 
contribution to patient care is proven. The ultimate goal is to achieve their sustainability, crucial to 45 
reaching their long-term integration and continuity into a given setting 19. Therefore, developing 46 
effective services and achieving their long-term implementation and sustainability in daily practice is 47 
crucial to explore innovative models of care that address population needs, and in turn supporting 48 
the advancement and future existence of the pharmacy profession. Pharmacy Practice Research is a 49 
critical enabler to achieve these goals.  50 
 51 
Pharmacy Practice Key Strategic Areas of Research 52 
The development, evaluation, implementation and sustainability of health interventions and patient-53 
care services represents a challenging process for pharmacy practice researchers. Traditional 54 
approaches such as the evaluation of health interventions through randomized controlled trials 55 
(RCTs), may not be sufficient to achieve practice and policy changes. A sole emphasis on the 56 
intervention’s evaluation phase, in detriment of the development and implementation phases make 57 
these interventions weaker, decreasing the chances of its future implementation20. To address this 58 
problem, pharmacy practice researchers can go through a number of stages in the planning and 59 
execution of their research, including design, impact evaluation, implementation, and sustainability. 60 
One of the potential failures in PPR has been trying to aggregate all these steps involved in health 61 
services research, rather than using a multistage approach. The Medical Research Council 62 
Framework, provides an structured approach to develop, evaluate, and implement complex 63 




quantitative, and mixed-method research approaches 20. This framework has been widely used in 65 
health services research, helping researchers make methodological and practical choices. The 66 
application of these techniques to Pharmacy Practice Research seems relevant, and an adaptation of 67 
the different phases that could be applied to health interventions and services are discussed below. 68 
 69 
 70 
Needs assessment - Identifying unmet population needs.   71 
Before the development of any health intervention or patient-care service, Pharmacy Practice 72 
Researchers must identify societal health needs that can benefit from pharmacists’ care or from 73 
wider healthcare system changes21. Unless a health intervention is able to respond to current or 74 
future societal needs, its future sustainability is likely to be compromised. This is undertaken through 75 
a health needs assessment, which is the systematic method of identifying unmet health and 76 
healthcare needs of a population and making changes to meet these unmet needs 21. Health needs 77 
assessment can provide clear objectives to design interventions and services which meet patient and 78 
population needs.  79 
Societal health needs have been defined as “the requirements at the individual, family, community 80 
and population levels -across the continuum of care- to achieve physical, cognitive, emotional, social, 81 
and spiritual wellbeing, taking into account the broad determinants of health” 22. Based on this 82 
definition, there are four key elements to be considered when undertaking a needs assessment. 83 
1) Firstly, local, community and global environments are to be examined, assessing health at 84 
an individual, community and population level. A population centred need perspective 85 
implies that: (a) there is an epidemiological approach to the problem, (b) there is a focus on 86 
the needs of individuals, communities and population (so disparities are reduced and health 87 
equity is maximised) and (c) community orientation and engagement is ensured22.   88 
2) It is important to recognise that needs, - i.e. gaps between a current and a desired state of 89 
being - can be objective or subjective and physical or psychological, and are likely to change 90 
over time.  91 
3) Efforts should be made to ensure a continuum of care, with integrated services ranging 92 
from illness prevention, health promotion, public health and screening, to chronic disease 93 
management, long-term care, and palliative care amongst others. This continuum of care 94 
would include services that are able to respond to current public healthcare crises (e.g. 95 




disease outbreaks). Effective needs assessments can potentially lead to integration of the 97 
results into planning and commissioning of local services21.  98 
4) Lastly, health is a broad concept influenced by multiple determinants which incorporate 99 
wider social and environmental factors. These must be carefully examined to fully 100 
understand the nature of the problem22. The analysis is key to determine if the identified 101 
determinants could be targeted with a pharmacy intervention and if this intervention would 102 
be within pharmacists’ scope of practice. Social factors influencing patient medicine use 103 
studied in social pharmacy, such as medicine and health-related beliefs, attitudes, rules, 104 
relationships, and processes, are just some of the many aspects to be considered in 105 
pharmacy practice research23.  106 
Specific attention should be paid to the local context in which this unmet need is identified and the 107 
feasibility of implementing an intervention. It must be noted that in some countries, especially in 108 
those with an ageing population, it is common to find a shortage of primary health care professionals 109 
such as physicians and nurses. This situation creates healthcare gaps that in some cases can be 110 
covered by pharmacists.  111 
It has been recommended that societal health needs are identified through a collaborative process 112 
that is patient-focused, culturally sensitive, evidence-based, and outcome-focused22. The process 113 
involves a range of research designs which will ultimately help to determine priorities for the most 114 
effective use of resources, balancing clinical, ethical, humanistic and economic factors21. Approaches 115 
during this phase include - but are not limited to - qualitative research (when an in-depth 116 
understanding of a particular phenomenon is needed, with a focus on perceptions and experiences 117 
from the perspective of the patient or other stakeholders)24, epidemiological approaches such as 118 
observational studies (used to describe the health status of populations and identify possible 119 
determinants of health outcomes) or systematic reviews and meta-analyses (used to synthesize the 120 
results of different studies when conflicting evidence exists in a given area).  121 
Intervention development – Designing and modelling processes and outcomes  122 
During this phase pharmacy practice researchers should aim at designing and modelling the 123 
intervention or patient-care service, in order to address the needs identified during the assessment 124 
phase. Identifying relevant evidence, Appraising other national and international services, and 125 
exploring the practical feasibility of an intervention in a given context are required. It is important to 126 




is fraught with problems. Moreover, poor design during the development of a service may result in a 128 
future implementation failure.  129 
Exploring existing theories, models, and frameworks from within pharmacy and other disciplines that 130 
are applicable to the service model is required. This is a vital preparatory step in designing a service. 131 
When based on theory, health interventions are more likely to have positive effects on its target 132 
population25. Theory can assist researchers to understand the likely outcomes for a complex 133 
intervention and therefore enable the modelling of the process. Process and outcome indicators that 134 
monitor the intervention’s performance during the evaluation, implementation and sustainability 135 
phases have to be established. Special attention should be paid to the identification of indicators 136 
that can be used in the future when monitoring the intervention’s fidelity (i.e. the degree to which 137 
the intervention is delivered as described)26.  138 
Many other components can be considered when developing a service that contributes to improved 139 
patient outcomes and adds value to healthcare. Some examples include patient and market demand, 140 
current local and national agreements, potential funders/payers, local policies, interdisciplinary care 141 
and collaborative practice models, pharmacists’ scope of practice and stakeholders’ views, amongst 142 
many others. Considering the different perspectives from all stakeholders involved is crucial for 143 
success. For example, involving patients in this stage has been associated with more effective 144 
services27, better relationship with the healthcare professional, and increased patient satisfaction28. A 145 
missed viewpoint or issue not identified early on may cause major difficulties during implementation. 146 
A possible approach during this stage could be the use of co-design (also known as participatory 147 
design, experience-based co-design, co-production, co-creation, or co-operative design). Co-design is 148 
increasingly being used in healthcare settings, including pharmacy29, to increase the participation and 149 
engagement of stakeholders in the development of health services.  Stakeholders could include 150 
individual patients, other health care professionals, groups, or organisations who may influence or be 151 
affected by decision-making on a particular action, aim, or policy. During a co-design process, future 152 
implementation and dissemination strategies are also covered.  153 
Intervention evaluation – Assessing the intervention’s feasibility and impact 154 
Evaluating the impact of a health intervention or patient-care service is a key step in the process of 155 
establishing the added value and contribution of pharmacists. The main objective of this phase is to 156 
assess either the efficacy or effectiveness of the intervention or service on pre-defined study 157 
outcomes. This step is critical to generate evidence on its benefits and convince potential service 158 




essential to consider the value from many other stakeholders’ perspectives involved in patient care 160 
to achieve a balanced overview of the intervention’s impact. This is often achieved using the Kozma’s 161 
ECHO (Economic, Clinical, Humanistic Outcomes) model30. It implies assessing the clinical impact (eg. 162 
clinical outcomes, important from the perspective of the health care provider), humanistic impact 163 
(e.g health-related quality of life, important from the patient perspective) and economic impact (e.g 164 
cost-effectiveness and cost-utility of the service, important from the policy maker and payer 165 
perspective). Examples of potential outcomes are shown in table 1.  166 
Once the study outcomes have been identified and defined, an appropriate study design should be 167 
selected to evaluate the intervention’s impact. The study design and length might be dependent on 168 
the study outcomes to be tested. RCTs are the gold standard to evaluate innovations in health and 169 
should always be considered as the most robust option. However, in some circumstances it is 170 
preferable to randomly assign groups or clusters of people instead of individuals. Cluster RCTs 171 
(cRCTs), widely used in health services research, have become essential to evaluate some types of 172 
interventions when contamination between study groups is to be avoided31 When a RCT or cRCT is 173 
not feasible, alternative experimental approaches can be considered. Pragmatic designs such as 174 
stepped-wedge cluster randomised trials, or sequential multiple assignment randomised trials 175 
(SMART) are expected to increase in the future32.  176 
Some complex interventions and services may incur in an expensive and long evaluation process. 177 
Therefore, where there is uncertainty about the practicability of a RCT or an alternative design, a 178 
feasibility study would be appropriate31. Different types of feasibility studies have been defined, 179 
according to their ultimate objective31. Feasibility studies are not designed to address the 180 
effectiveness of an intervention. Rather, they are used to determine whether an intervention is 181 
appropriate for further evaluation33. They also allow weaknesses to be identified, methods and 182 
procedures to be tested and refined, and they can offer significant information regarding the design 183 
so potential problems do not arise in the evaluation and implementation phases20. Feasibility studies 184 
can address the stakeholders’ intervention acceptability (e.g. patients, providers, other health care 185 
professionals, policy makers), intervention demand, participant recruitment, retention rates, 186 
intervention’s implementability in a given setting or its practicality. They can also provide valuable 187 
information to estimate potential effect sizes and sample sizes for the main trial.  Potential research 188 
approaches and methods vary depending on the study focus, and these often include a mix of 189 
qualitative and quantitative approaches through structured or semi structured interviews, nominal or 190 




more than one feasibility study might be needed. Once the appropriate feasibility testing has been 192 
finalised, one should be confident the intervention’s effectiveness can be evaluated in a larger trial.   193 
Intervention implementation– incorporating innovations into practice 194 
There is extensive evidence supporting the role of pharmacists in a range of disease states. However 195 
these benefits cannot accrue unless there is effective implementation34. Implementation science 196 
emerged to address the challenges associated with the incorporation of evidence-based innovations 197 
into practice35, seeking to understand and work within real world conditions36. Like in other 198 
disciplines, implementation research has become a rapidly progressing interest for pharmacy 199 
practice researchers. Numerous frameworks, theories and models have been developed to address 200 
the science to practice gap, which have predominantly been targeted to specific disciplines, including 201 
pharmacy37. These conceptual approaches, which vary depending on their ultimate objective, have 202 
been acknowledged as a key element to facilitate the implementation of health innovations into 203 
practice 34,38. For example, process models describe a number of implementation stages (e.g. 204 
exploration, adoption, installation/preparation, initial implementation, full operation) that guide the 205 
implementation process. Determinant frameworks, classic theories and implementation theories 206 
usually aim to understand and explain what factors influence implementation outcomes.   Finally, 207 
evaluation frameworks provide a range of outcome indicators (e.g. acceptability, adoption, 208 
appropriateness, costs, feasibility26) that can be used to determine implementation success26. The 209 
application of these approaches vary depending on the implementation research question. 210 
Nevertheless, some criteria exist to help researchers identify an appropriate approach, instead of 211 
using theories that are convenient but not appropriate to meet the research objectives39.  212 
Different implementation research designs have been suggested, some of which have been 213 
successfully applied in pharmacy18,40–42. Hybrid designs, in which design components of clinical 214 
effectiveness and implementation research are blended according to the study’s main objective, are 215 
widely used and reported in the implementation science literature43. Experimental epidemiological 216 
designs already described, qualitative and mixed method approaches such as quality improvement 217 
studies and participatory action research are common36. Extensive research has been undertaken to 218 
explore barriers and facilitators for services implementation. However, there has been a call for more 219 
rigorous implementation studies in pharmacy, which should consider using implementation theories, 220 
frameworks or models and report on appropriate implementation outcomes44.  Therefore, 221 
researchers may want to question themselves: Has an implementation theory, model or framework 222 




objectives? Have implementation process and outcome indicators being defined? How are they going 224 
to be assessed? 225 
Sustainability - achieving the intervention’s sustainment  226 
Sustainability is the last phase in the creation of health interventions and patient-care services, which 227 
is becoming increasingly important for health services researchers and policy-makers. Once an 228 
evidence-based intervention has been implemented in practice, the ultimate objective is to achieve 229 
its long-term sustainability. Despite its importance, there is scarce evidence on how to achieve long-230 
term sustainability of health interventions and services once the implementation phase is over. In 231 
fact, this step is not considered in the MRC framework.  232 
Advancements in this area have resulted in the development of conceptual approaches to guide, 233 
identify determinants and even evaluate the sustainability of innovations in health care settings. 234 
However, there is some debate on how this important stage should be conceptualisedi45. 235 
Nevertheless, a definition for pharmacy practice research has been suggested“Sustainability is a 236 
phase in the process of a professional pharmacy service, in which the service previously integrated 237 
into practice during the implementation phase is routinized and institutionalized over time to achieve 238 
and sustain the expected service outcomes” 19. According to this definition, sustainability seems to be 239 
conceptualised by two dimensions: routinisation and institutionalisation. These elements have also 240 
been identified as essential to achieve sustainable interventions and services in pharmacy46. In 241 
sustainability, routinisation refers to the maintenance of the pharmacy's routine for the service 242 
provision, through continuous improvement of the service’s protocol and components. According to 243 
this element, sustainability is a dynamic process, with evaluation and continuous monitoring of the 244 
service’s performance being critical to ensure the service is working effectively and producing its 245 
expected outcomes (as per the evaluation and implementation phase). This continuous monitoring 246 
can lead to a service adaptation if needed. Service adaptation is given high relevance in the literature 247 
and has been described as essential to ensure the long-term sustainability of evidence-base 248 
interventions46,47 However, there is uncertainty on how adaptation and fidelity (i.e. the degree to 249 
which an intervention or program is delivered as intended) should be balanced. 250 
Institutionalisation refers to the gradual adaptation of the pharmacy's context, structures, and 251 
processes, to the provision of the service. Within the concept of institutionalisation, three 252 
interrelated performance domains (environment, social and economic) with core factors across each 253 
domain, are hypothesised to moderate the service’s sustainability. Some of these factors include but 254 




Pharmacy practice research key priorities during the sustainability phase should aim to validate and 256 
empirically test an evaluation framework in pharmacy. Other areas of interest could include 257 
developing monitoring systems for the intervention’s performance through digital platforms, as well 258 
as adaptation and optimisation mechanisms, using innovative approaches such as machine learning. 259 
The development and evaluation of tailored sustainability strategies, targeted at the different 260 
sustainability factors, are to be studied. Research approaches imported from other disciplines such as 261 
change management, service value networks or service operations management seem to be 262 
potentially useful in advancing in this area.  263 
The role of pharmacy practice research in universities 264 
As dynamic institutions, universities have to evolve to identify and meet the demands of the society, 265 
by producing graduates t`hat are able to address those current and future demands.  Over the past 266 
years, pharmacy has increasingly been using research in practice. One of the main objectives has 267 
been to evaluate pharmacists’ contribution to new models of care through some of the approaches 268 
previously described. Schools of Pharmacy in some countries have significantly contributed to the 269 
advancement of the pharmacy profession either by university institutions or associated pharmacy 270 
practice research centres48. Most of their research is guided and driven by national local needs, such 271 
as chronic disease management in developed countries48 or disease prevention in developing 272 
countries. Their findings have contributed to expand the role of pharmacists in local and global 273 
environments. Despite this and possibly due to it social component, pharmacy practice research has 274 
often been considered as a “soft” science in many pharmacy schools, leading into an erroneous 275 
perception of being a less valid scientific field.  276 
Pharmacy practice research often integrates concepts and methods from disciplines outside 277 
pharmacy such as psychology, pharmacoeconomics, public health or implementation science, which 278 
stimulates interdisciplinary collaborations. There is evidence collaborative national and international 279 
research in this area is growing, showing an increased contribution to global health research50. To 280 
continue with its innovative contribution to the profession and the society, Universities need to 281 
invest in pharmacy practice research, creating departments, research centres, and allowing access to 282 
research funding that allow advances in the discipline. Professional organisations should 283 
continuously inform Universities on the graduate attributes that are needed in the current and 284 
future pharmacy workforce49. Universities, health professional organisations, governments, and 285 
consumer groups should work collaboratively to continuously shape the future of the pharmacy 286 
profession, lead innovation, and expand Pharmacy Practice opportunities. This could be done at 287 




provides leadership for national pharmacy professional organisations, which in turn provide the 289 
impetus for setting national standards.  290 
 291 
International Pharmaceutical Federation and Pharmacy Practice Research  292 
The International Pharmaceutical Federation (FIP) is an international organization representing 293 
pharmacists and pharmaceutical scientists. Since its foundation in 1912, FIP’s priorities have evolved 294 
in order to meet the needs and expectations of the profession, manifested through an increase of 295 
healthcare services and integration of emerging scientific innovations in the practice of the 296 
pharmacy. As stated in FIP’s 2020 vision and strategic plan, its ultimate vision is to "improve global 297 
health by advancing Pharmacy Practice and science to enable better discovery, development, access 298 
to and safe use of appropriate, cost-effective, quality medicines worldwide”.  299 
 300 
The Board of Pharmaceutical Sciences (BPS) deals with FIP’s scientific activities, with the ultimate 301 
objective of contributing to the improvement of world health, mainly through disease prevention 302 
and treatment strategies. Within the BPS, there are six Special Interest Groups (SIG’s), which are in 303 
charge of continuously developing initiatives to assist FIP and its member organisations achieve this 304 
objective. In 2016, the BPS provided the opportunity to establish the Pharmacy Practice Research 305 
SIG (PPR SIG) as one of its pharmaceutical sciences areas of research. It was created with the main 306 
scope of increasing Pharmacy Practice contributions to global health through the provision of 307 
greater access to the latest high-quality international pharmacy practice research. Based on this 308 
objective, the PPR SIG also aims to cultivate an international forum for the dissemination of quality, 309 
international pharmacy practice research for all stakeholders and stimulate communication, 310 
discussion, networking and collaboration between international Pharmacy Practice stakeholders, 311 
including pharmacists and pharmaceutical scientists for the advancement of best practice. Research 312 
areas and efforts will be targeted at local and global priorities, with the ultimate objective of 313 
improving pharmacists’ contribution to global health.  314 
 315 
Call to action for Pharmacy Practice Research, Pharmacy Practice Education and Practice 316 
of Pharmacy  317 
Based on the elements discussed in this paper, the following actions are proposed: 318 
• Adopting the Pharmacy Practice definition suggested in this paper.  319 
• Undertaking a societal health needs assessment before the development of 320 




• Using robust epidemiological research designs when evaluating health 322 
interventions. When sufficient evidence is available, this should be synthesised 323 
using robust meta-analyses.  324 
• Applying innovative research methods to address challenges that cannot be solved 325 
with current research approaches. This is especially relevant for addressing the 326 
current science-to-service gap, during implementation and sustainability phases.  327 
• Implementing Pharmacy Practice teaching and research in all pharmacy 328 
curriculums. 329 
• Stimulating global collaboration across pharmacy practice researchers and 330 
educators in order to support teaching and research.  331 
• Consolidating a distinctive body of knowledge by creating consistent terminology 332 
and thesaurus and publishing in pharmacy journals when disseminating pharmacy 333 
practice research outputs. 334 
• Reinforcing local and global pharmacy organisations’ role, support and contribution 335 
to Pharmacy Practice Research for the advancement of best practice. 336 
 337 
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